Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs

BACKGROUND: Indication for treatment with osimertinib after first/second generation (1/2G) epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) resistance depends on T790M mutation detected by rebiopsy. The aim of our study was to analyze the data on clinical practice at our hospita...

Descripción completa

Detalles Bibliográficos
Autores principales: Ninomaru, Taira, Hata, Akito, Kokan, Chiyuki, Okada, Hideaki, Tomimatsu, Hirotaka, Ishida, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952804/
https://www.ncbi.nlm.nih.gov/pubmed/33475261
http://dx.doi.org/10.1111/1759-7714.13822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952804/
https://www.ncbi.nlm.nih.gov/pubmed/33475261
http://dx.doi.org/10.1111/1759-7714.13822

Ejemplares similares